biostudies-literatureUnknown78(9)Almeida OP<h4>Importance</h4>One in 3 adults experiences clinically significant symptoms of depression during the first year after a stroke, but evidence to support the use of antidepressants in this population remains scant.<h4>Objective</h4>To investigate whether daily treatment with 20 mg of fluoxetine hydrochloride reduces the proportion of people affected by clinically significant symptoms of depression after stroke.<h4>Design, setting, and participants</h4>In this secondary analysis of the Assessment of Fluoxetine in Stroke Recovery parallel-group, randomized (1:1 assignment), double-blind, placebo-controlled clinical trial, 1221 participants in Australia, New Zealand, and Vietnam were recruited between January 11, 2013, and June 30, 2019, and were followed up for 6 months. Adults aged 18 yearJAMA neurology1072-1079https://www.ebi.ac.uk/biostudies/studies/S-EPMC8329781biostudies-literatureDepression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery: The AFFINITY Randomized Clinical Trial.PMC8329781Abraham ALe THLe TDCarr MWilliams CDo CMBailey AHoang HVLe STDonnan GATaylor CNguyen YHHankey GJGopinath SSpooner MAnderson CSRamirez DNguyen HNWalker SJan SPatel VDuckett ENguyen HTRatcliffe MSahathevan RPhan HTLe TVLevy SDelcourt CLow EAssessment of Fluoxetine in Stroke Recovery (AFFINITY) Trial CollaborationThach KNTran GKHourn MWhite JMalavera AMassey JJones BStockle PNguyen GTLopez MLam NTTrewin BO'Rourke FLe QNDuroux MMacdonald BSanctuary CBurdusel CNguyen HBHartwell TMead GEGawarikar YVuong TXMughal NHa OKAbeysuriya KLe BVHoang UTDo PTCalic ZMccormack SAlmeida OPShandiz EEMaxwell VHickey KDunne JKho LFaux SEdmonds GDennis MSMcCoy RLatif MDrummond CPepperell BLung TMurray VHuynh HQDavis SChristley JTruong PTNguyen VTCarter GMurray ADavenport CVu LTNgo NDLundstrom EBroughton PMcDonald ADang HHNguyen DTEvans ASangvatanakul FMcNaughton HDao NTLi QLindley RIDaines MWong LKTrinh PTBolitho SChen CBergqvist JDang HCLe HTMcQueen RGhia DBoyle KVeitch KLu HNDinh LVMasterson AJude MNguyen TBSouthwell LRobertson RNguyen TDCheuk GNguyen CVMohr KNguyen THVo LNSurendran VLe VCCoyle HHayes HBoudville AO'Loughlin NTabesh MNguyen TAKuang YMCappelen-Smith CRigney LLiu YNguyen TTO'Dea JNguyen TVKatrak PJackson DTsoleridis JHewitt LNguyen BTEwing MRedpath CCelestino SNguyen SHDao PVTran TTTran TVGranger AHan HTLeung QTran TNDinh NNNguyen SVVallat WDo Nguyen DChalissery JPollack MLe LCTruong LVHackett MDeane LNguyen ANPage KBlacker DLe KKAkbari SRay EKieu DVFlicker LPham THWheelwright DWijeratne TMoey AMarkus RNham BZagami ALanford JDang TNPham TTBaldwin CDinh HHSiracusa ELe LMMai HVKleinig TMahawish KPeterson SMai YBBui TCRollason MPham CVAskar SKernaghan LDinh HTDoan BTOakley KDay SFu VDam AHNguyen PDLee LTruong NQPham SPShivlal DYi QPepper ENgo HTPriglinger MKieu TVTang MLee ADao KDDang THCheng QGeraghty RNathani DPham BNBates TRDeCaigney SWithanage ALallu BRuddell KHerbert RTran PHPham AGMcLennan CRoberts CChoong HKnight KSilver GBrown AWinker ACordato DWithiel TO'Neill MRees MNguyen -BNguyen MTPham QNBurnet HDinh TQKumar RVu TTLe OTBillot LDuque VTran HTLuong DHNguyen NHField DOrmond SPham QBLe NShone STan BLNguyen LTNguyen LVBaines HWhittaker KAClaxton APhua CDam LCWu ATong TMBompoint SMcDougall AJTarrant LDuong CDKhuong DQNguyen MHDo VPHair CHuynh NXEtherton-Beer CBui TNKunchok AGommans JVo TVSchmid DNew PTan ALMamun ANagesh KKrause MBarrett SMai TDBunce LNgo TKThai HNguyen LHNgo TBTran LKLaubscher SCarcel CLe NTChua CLe LTMDo CQFord AHong UHMorgan PLe NHfalseDepression Outcomes Among Patients Treated With Fluoxetine for Stroke Recovery: The AFFINITY Randomized Clinical Trial.<h4>Importance</h4>One in 3 adults experiences clinically significant symptoms of depression during the first year after a stroke, but evidence to support the use of antidepressants in this population remains scant.<h4>Objective</h4>To investigate whether daily treatment with 20 mg of fluoxetine hydrochloride reduces the proportion of people affected by clinically significant symptoms of depression after stroke.<h4>Design, setting, and participants</h4>In this secondary analysis of the Assessment of Fluoxetine in Stroke Recovery parallel-group, randomized (1:1 assignment), double-blind, placebo-controlled clinical trial, 1221 participants in Australia, New Zealand, and Vietnam were recruited between January 11, 2013, and June 30, 2019, and were followed up for 6 months. Adults aged 18 year2021-01-01T00:00:00Z2021 Sep2025-04-04T09:37:32.881Z2025-04-04T09:37:32.881ZS-EPMC83297813433871410.1001/jamaneurol.2021.2418